What has Covid-19 taught us about virtual clinical trials?

The public health crisis of Covid-19 not only led to the rapid scale-up of virtual health delivery, it also accelerated the use of decentralized clinical trials. Decentralized clinical trials are regarded as a way to increase and maintain clinical trial participation, reduce the time to recruit participants, and have additional advantages.

At the MedCity INVEST PharmaTech, scheduled for Tuesday July 26, the virtual conference will cast a spotlight on this and related topics such as AI to support drug development, the future of digital medicines, and more.

To see the full agenda, click here.

To register free of charge, click here.

When going to the hospital – very often the site of clinical trials – is no longer an option because of a pandemic, that requires the very reimagining of how clinical trials are designed. But can virtual, decentralized or siteless clinical trials be as effective as traditional trials? What are the pros and cons of running such trials?

THREAD Research CEO John Reites will moderate a discussion on this topic with speakers including:

We’re also looking for startups to pitch as part of our Pitch Perfect contest. The theme for this conference: Reinventing clinical trials.

Of the many post-pandemic realities, one is the need to make clinical trials more decentralized. Startups in this category are developing products – both technology and services – that can help transform in-person ,site-based clinical trials into purely clinical trials or bring in more digital elements to traditional clinical trial processes.

To apply to pitch, click here.

For sponsorship queries, contact our publisher Ken Montgomery: kmontgomery@medcitynews.com

Image: exdez, Getty Images